Presentation Description / Summary: Osteosarcoma (OS) is an aggressive pediatric/adolescent/young adult malignancy and is the most common malignant bone tumor in this patient population. Similarly, canine OS is an aggressive, naturally-occurring bone tumor of dogs that is >10x more common than in humans. Patients with metastatic or relapsed disease have dismal outcomes, with long-term survival rates less than 30% despite aggressive salvage regimens. A comprehensive genomic framework of canine OS is needed to correlate the biologic and clinical facets of the disease in dogs, and to understand how they relate to what is known in human OS. To address this gap in knowledge, we have created the DOG2 project (Decoding the Osteosarcoma Genome in Dogs (DOG2)). The goals of DOG2 are to gain improve knowledge of comparative OS cancer biology to enhance dog to human translation, and to discover new drug targets and companion biomarkers in support of improved outcomes for humans. In this presentation we will share our progress to establish a comparative pathologic, immunologic and genomic framework of OS in pet dogs. This includes various genomic profiling, immunohistochemical and computational modelling methods for identifying biologically and prognostically distinct subgroups of canine OS.
Learning Objectives:
Summarize how canine OS can be molecularly characterized to identify a genomic framework that facilitates direct comparison of the disease in dogs to recently identified subtypes of human OS.
Observe how the comparative immunological landscape of canine OS, defined through transcriptomic profiling via the Nanostring Canine IO panel and histopathological immune cell profiling, can provide improved insight into OS-related immunobiology in dogs
Appreciate how comparative tumor boards are an invaluable part of bridging the worlds of veterinary and physician oncology
.jpg "Amy K. LeBlanc, DVM, DACVIM (Oncology) photo")
